Latest news

• Nektar’s opioid analgesic slammed with FDA panel rejection

  High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Although the rejection is a blow to Nektar, the opioid painkiller had already been somewhat

• Insys gets bankruptcy court okay for Subsys sale

  Opioid product was focus of racketeering charges. Insys Therapeutics has been given the green light to sell its Subsys opioid product – the focus of racketeering charges that forced the company to ... Subsys is a sublingual spray formulation of fentanyl

• Nektar confirms BMS deal for NKTR-214 is on track

  Almost forgotten among the interest in Nektar’s immuno-oncology pipeline – which also includes three other candidates in clinical trials – is NKTR-181, a first-in-class, abuse-deterrent opioid analgesic ... The drug promises to deliver pain relief

• Endo faces industry-first FDA call to pull its opioid painkiller

  The painkiller was first approved in 2006 to manage moderate-to-sever pain when a continuous, around-the-clock opioid analgesic was needed for an extended period of time, but an ... abuse.”. Opioid overdoses killed 33, 000 Americans in 2015 - with half

• Purdue gets FDA nod for abuse-deterrent painkiller

  Purdue Pharma has expanded its portfolio of opioid analgesic drugs following FDA approval of Hysingla ER, a once-daily product designed to resist abuse. ... The new product will compete in the marketplace against products such as Zogenix' 12-hour Zohydro